Read More Pharma Industry News TWi Biotechnology begins Phase 2 trial for AC-203 in epidermolysis bullosa patients TWi Biotechnology, a Taiwanese biopharmaceutical company, has initiated the enrollment of patients in a pivotal Phase 2 clinical… bypharmanewsdailyOctober 21, 2018
